DELIVER
An International, Double-blind, Randomised Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Morbidity and Mortality in Patients with HFpEF
- Stadium
- klaar
- Middel
- dapagliflozin
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 5 november 2018
- Last Patient In
- 31 oktober 2020
- Last Patient Last Visit
- 27 maart 2022
National Lead
dr. C.J.W. Borleffs
Cardioloog
Contact Kantoor
